MEDIF
Price
$0.05
Change
-$0.00 (-0.00%)
Updated
Aug 8 closing price
Capitalization
21.12M
NPPNY
Price
$5.37
Change
+$0.03 (+0.56%)
Updated
Aug 7 closing price
Capitalization
1.5B
Interact to see
Advertisement

MEDIF vs NPPNY

Header iconMEDIF vs NPPNY Comparison
Open Charts MEDIF vs NPPNYBanner chart's image
Medipharm Labs
Price$0.05
Change-$0.00 (-0.00%)
Volume$96.17K
Capitalization21.12M
Nippon Shinyaku
Price$5.37
Change+$0.03 (+0.56%)
Volume$1.42K
Capitalization1.5B
MEDIF vs NPPNY Comparison Chart in %
Loading...
MEDIF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NPPNY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MEDIF vs. NPPNY commentary
Aug 12, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MEDIF is a Hold and NPPNY is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 12, 2025
Stock price -- (MEDIF: $0.05 vs. NPPNY: $5.37)
Brand notoriety: MEDIF and NPPNY are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: MEDIF: 79% vs. NPPNY: 75%
Market capitalization -- MEDIF: $21.12M vs. NPPNY: $1.5B
MEDIF [@Pharmaceuticals: Generic] is valued at $21.12M. NPPNY’s [@Pharmaceuticals: Generic] market capitalization is $1.5B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $66.04B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.62B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MEDIF’s FA Score shows that 0 FA rating(s) are green whileNPPNY’s FA Score has 2 green FA rating(s).

  • MEDIF’s FA Score: 0 green, 5 red.
  • NPPNY’s FA Score: 2 green, 3 red.
According to our system of comparison, NPPNY is a better buy in the long-term than MEDIF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MEDIF’s TA Score shows that 4 TA indicator(s) are bullish while NPPNY’s TA Score has 4 bullish TA indicator(s).

  • MEDIF’s TA Score: 4 bullish, 3 bearish.
  • NPPNY’s TA Score: 4 bullish, 1 bearish.
According to our system of comparison, both MEDIF and NPPNY are a good buy in the short-term.

Price Growth

MEDIF (@Pharmaceuticals: Generic) experienced а -1.36% price change this week, while NPPNY (@Pharmaceuticals: Generic) price change was +0.47% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +2.48%. For the same industry, the average monthly price growth was +8.38%, and the average quarterly price growth was +79.14%.

Industries' Descriptions

@Pharmaceuticals: Generic (+2.48% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NPPNY($1.5B) has a higher market cap than MEDIF($21.1M). MEDIF YTD gains are higher at: 22.518 vs. NPPNY (-19.127). NPPNY has higher annual earnings (EBITDA): 36.5B vs. MEDIF (-4.75M). NPPNY has more cash in the bank: 66B vs. MEDIF (8.44M). MEDIF has less debt than NPPNY: MEDIF (125K) vs NPPNY (2.55B). NPPNY has higher revenues than MEDIF: NPPNY (154B) vs MEDIF (43M).
MEDIFNPPNYMEDIF / NPPNY
Capitalization21.1M1.5B1%
EBITDA-4.75M36.5B-0%
Gain YTD22.518-19.127-118%
P/E RatioN/A6.56-
Revenue43M154B0%
Total Cash8.44M66B0%
Total Debt125K2.55B0%
FUNDAMENTALS RATINGS
MEDIF vs NPPNY: Fundamental Ratings
MEDIF
NPPNY
OUTLOOK RATING
1..100
1550
VALUATION
overvalued / fair valued / undervalued
1..100
91
Overvalued
8
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9518
PRICE GROWTH RATING
1..100
5961
P/E GROWTH RATING
1..100
10076
SEASONALITY SCORE
1..100
503

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NPPNY's Valuation (8) in the null industry is significantly better than the same rating for MEDIF (91). This means that NPPNY’s stock grew significantly faster than MEDIF’s over the last 12 months.

NPPNY's Profit vs Risk Rating (100) in the null industry is in the same range as MEDIF (100). This means that NPPNY’s stock grew similarly to MEDIF’s over the last 12 months.

NPPNY's SMR Rating (18) in the null industry is significantly better than the same rating for MEDIF (95). This means that NPPNY’s stock grew significantly faster than MEDIF’s over the last 12 months.

MEDIF's Price Growth Rating (59) in the null industry is in the same range as NPPNY (61). This means that MEDIF’s stock grew similarly to NPPNY’s over the last 12 months.

NPPNY's P/E Growth Rating (76) in the null industry is in the same range as MEDIF (100). This means that NPPNY’s stock grew similarly to MEDIF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MEDIFNPPNY
RSI
ODDS (%)
N/A
Bullish Trend 4 days ago
27%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
90%
Bearish Trend 4 days ago
54%
Momentum
ODDS (%)
Bullish Trend 4 days ago
89%
Bullish Trend 4 days ago
35%
MACD
ODDS (%)
Bullish Trend 4 days ago
88%
Bullish Trend 4 days ago
44%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
90%
Bullish Trend 4 days ago
28%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
87%
Bullish Trend 4 days ago
25%
Advances
ODDS (%)
Bullish Trend 22 days ago
84%
N/A
Declines
ODDS (%)
Bearish Trend 13 days ago
90%
N/A
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
90%
Bullish Trend 4 days ago
45%
Aroon
ODDS (%)
N/A
N/A
View a ticker or compare two or three
Interact to see
Advertisement
MEDIF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NPPNY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MDVYX10.260.09
+0.88%
MassMutual Diversified Value Svc
LZUOX17.610.12
+0.69%
Lazard US Equity Focus Open
JDBRX49.080.20
+0.41%
Janus Henderson Balanced R
MCVAX11.04N/A
N/A
Transamerica Mid Cap Value Opps A
FSDAX24.31-0.06
-0.25%
Fidelity Select Defense & Aerospace

MEDIF and

Correlation & Price change

A.I.dvisor tells us that MEDIF and SWGHF have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that MEDIF and SWGHF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MEDIF
1D Price
Change %
MEDIF100%
-5.42%
SWGHF - MEDIF
29%
Poorly correlated
N/A
GLASF - MEDIF
25%
Poorly correlated
+3.97%
AAWH - MEDIF
23%
Poorly correlated
+11.58%
TCNNF - MEDIF
22%
Poorly correlated
+5.52%
CURLF - MEDIF
22%
Poorly correlated
+13.97%
More

NPPNY and

Correlation & Price change

A.I.dvisor tells us that NPPNY and MKKGY have been poorly correlated (+11% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NPPNY and MKKGY's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NPPNY
1D Price
Change %
NPPNY100%
N/A
MKKGY - NPPNY
11%
Poorly correlated
+3.46%
MEDIF - NPPNY
11%
Poorly correlated
-5.42%
OVATF - NPPNY
9%
Poorly correlated
N/A
OMID - NPPNY
1%
Poorly correlated
+25.79%
MGWFF - NPPNY
0%
Poorly correlated
N/A
More